Sign Out
Pregnancy: No clinical data are available about the use of this medicinal product by pregnant women. Studies with manidipine on laboratory animals do not provide sufficient results on foetal development (see Pharmacology: Toxicology: Preclinical safety data under Actions). Since other medicinal products in the dihydropyridine family have been shown to be teratogenic in animal species, and since the potential clinical risk is not known, manidipine should not be used during pregnancy.
Lactation: Manidipine and its metabolites are excreted in large quantities in rat milk. As it is not known whether or not manidipine is excreted in human milk, the use of manidipine must be avoided during lactation. If manidipine treatment is necessary, breast-feeding must be discontinued.
Fertility: Reversible biochemical changes in the head of spermatozoa which can impair fecundation have been reported in some patients treated by channel blockers.
